Abstract. High-risk human papillomavirus (HPV) is the primary cause of cervical carcinoma (CC). Viral integration into the host chromosomes is associated with neoplastic progression, and epigenetic changes may occur as a result. The objective of the present study was to analyze HPV L1 gene methylation and to compare the use of quantitative polymerase chain reaction (qPCR), *in situ* hybridization (ISH) and L1 methylation analysis as methods for detecting HPV integration. Cervical scrapes or biopsy samples positive for HPV 16 or 18, from 187 female patients with CC, squamous intraepithelial lesions (SILs) or no intraepithelial lesion (non-IL) were analyzed. Methylation of the L1 gene was determined using bisulfite modification followed by PCR, and HPV integration was subsequently analyzed. HPV 16 L1 gene methylation was revealed to increase with histological grade, with statistically significant differences observed as follows: Low-grade SIL vs. CC, *P*<0.0001 and non-IL vs. CC, *P*<0.0001. HPV 18 L1 gene methylation also increased according to histological grade, however, no statistically significant differences were observed. Methylation at CpG site 5608 of the HPV 16 L1 gene was associated with all grades of cervical lesions, whereas methylation at CpG site 5617 demonstrated the strongest association with CC (odds ratio, 42.5; 95% confidence interval, 4.7-1861; *P*<0.0001). The concordance rates between the various methods for the detection of the physical status of HPV 16 and HPV 18 were 96.1% for qPCR and ISH, 76.7% for qPCR and L1 gene methylation, and 84.8% for ISH and L1 gene methylation. In conclusion, methylation of the HPV 16 L1 gene increases significantly according to the grade of the cervical lesion, and methylation at CpG sites 5608 and 5617 of this gene may be used as prognostic biomarkers. ISH and L1 gene methylation have good concordance with qPCR with regards to the detection of HPV integration. Therefore, these are useful methods in determining the physical state of HPV.

Introduction

The primary cause of cervical carcinoma (CC) is persistent infection with high-risk human papillomavirus (HR-HPV) (1). The infecting HPV type, viral persistence, viral integration status and viral load contribute to the pathogenesis of CC (1). Among the HR-HPVs, HPV 16 and 18 are the most common in cases of CC globally (2).

CC was the fourth most common type of cancer among women globally in 2012 (3). In Mexico, it is the second most frequent cancer type amongst women and the most common female cancer type in women aged 15-44 years, with ~9.4% of women in the general population estimated to harbor cervical HPV infection, and 70.2% of all CC cases being attributed to HPV 16 or 18 (4). In the state of Guerrero in Southern Mexico, CC is the most common type of cancer in women. This state also has the fifth highest mortality rate from CC in the country (5). HPV 16 is the most common genotype in CC, followed by HPV 18 (6).

Cytological screening of Papanicolaou smears has reduced the incidence and mortality rates of CC. However, the low sensitivity and low reproducibility of cytological tests, despite the availability of HPV DNA testing as an adjunct procedure, has resulted in a lack of discrimination between transient and persistent infections (7).

HPV genomes replicate as episomal DNA during productive infections, and the integration of HR-HPV genomes into the host chromosome has been associated with neoplastic progression (8). The E2 HPV gene has been revealed to be...
broken more frequently compared with other sites (9-11). This break results in a loss of the negative-feedback control for the transcription of oncogenes E6 and E7 (12), enabling tumor development and progression (13,14). Therefore, HPV integration into the human genome is considered to be a notable event in cervical carcinogenesis. Although certain studies suggest that integration is a late event (14,15), others have proposed that integration may be an early event in carcinogenesis (16-20).

Based on this information, a quantitative polymerase chain reaction (qPCR) analysis method that uses the PCR amplification of the E2 and E6 open reading frames (ORFs) and a calculation of E2/E6 ratios in order to measure integration was developed (20). Identification of the integrated HPV has been proposed as a useful biomarker for lesion progression. Nevertheless, qPCR is a technically difficult method for use in clinical practice.

HPV integration may render viral and cellular genes susceptible to epigenetic changes, which may in turn regulate their expression (21). The L1 gene in HPV 16 and 18 has been observed to be frequently hypermethylated in cancer, compared with the infrequent methylation observed in premalignant lesions (18,22-26). It has been reported that the methylation of the HPV 16 L1 gene indicates integration and is associated with the grade of premalignant lesions and cancer types, as well as being a potential clinical marker of CC progression (18,27-29).

HPV integration and the grade of cervical neoplasia may also be identified using a biotinyl tyramide-based in situ hybridization (ISH) method. Punctate signals within the nucleus are consistent with episomal DNA (30-33). The use of novel tools alongside the cytological diagnosis of premalignant lesions may improve the sensitivity of this method, increasing its effectiveness, which would reduce the number of misdiagnosed cases and prevent unnecessary invasive treatments in women diagnosed with premalignant lesions. As HPV integration is a viral marker for lesion progression, it is important to use a technically simple and affordable method for the detection of HPV integration in clinical practice.

The aim of the present study was to analyze L1 gene methylation in cervical lesions of various grades, and to perform a comparative analysis between L1 methylation, ISH and qPCR as methods for determining the physical status of HPV 16 and 18.

Analysis of the methylation of the HPV 16 and HPV 18 L1 gene. Methylation of the L1 gene from HPV 16 and 18 was analyzed using a bisulfite conversion reaction, wherein unmethylated cytosine is converted into uracil, followed by PCR amplification. DNA (400-1,200 ng) from cervical samples was treated with bisulfite for 150 min at 64°C using an EZ DNA Methylation-Gold™ kit (Zymo Research Corp., Irvine, CA, USA), according to the manufacturer’s protocol.

The 5’ and middle regions of the HPV 16 L1 gene, and the 5’ and 3’ regions of the HPV 18 L1 gene were amplified using PCR. Amplifications were performed using 100-150 ng bisulfite-treated genomic DNA, 6 µl AmpliTag Gold® 360 Master mix (Applied Biosystems; Thermo Fisher Scientific, Inc., Waltham, MA, USA), 1 µmol sense primer and 1 µmol antisense primer in a 15-µl final reaction volume. The following primers were used for amplification: HPV 16 L1 5’ region forward, 5’-TGTTGATGTAGGTATTTTAATT TATATTTTAGTTCCA-3’ and reverse, 5’-TATACCCACACCTATAACTACC-3’ as previously described by Oka et al (28) at 59°C, HPV 16 L1 middle region forward, 5’-ATTATGATTATTTTTAAATGTTGTAGAAT-3’ and reverse, 5’-AAAATTAATTATCCCCAACAAATACC-3’ as previously described by Brandsma et al (27) at 54°C. HPV 18 L1 5’ region forward, 5’-GGGTAGTTTGTATTGGTT GGT-3’ and reverse, 5’-CTATACCCACAACAAATACC-3’ as previously described by Badal et al (38), at 39°C.

The present study was approved by the Bioethics Committee of the Autonomous University of Guerrero. Written informed consent was obtained from all patients prior to the study.

The samples were studied to analyze L1 gene methylation in the different grades of cervical lesion and to compare L1 methylation, ISH and qPCR as methods for determining the physical status of HPV 16 and 18.

Materials and methods

Clinical specimens. A total of 187 female patients between 28-51 years of age were enrolled in the present study, selected from the 1,115 female residents of the state of Guerrero in Southern Mexico. The patients were admitted to the Unit for Early Diagnosis of Cervical Cancer and HPV at the Autonomous University of Guerrero (Chilpancingo, Mexico) and the Cancer Institute of the State of Guerrero (Acapulco, Mexico) between November 2013 and August 2015. Cervical scrapes or biopsies were collected for cytomorphological examination using liquid cytology or histological examination. Papanicolaou smears were reviewed by a certified cytopathologist and biopsies by a certified histopathologist. DNA was extracted from the cervical scrapes or biopsies using the phenol-chloroform isomyl alcohol method (34) for HPV detection and genotyping with an INNO-LiPA genotyping kit (Fujirebio Europe, Gent, Belgium) (35), without amendment and according the manufacturer's protocol.

All patients included in the current study presented with HPV 16 (n=154) or HPV 18 (n=33), and CC (n=33), high-grade squamous intraepithelial lesion (HSIL; n=13), low-grade squamous intraepithelial lesion (LSIL; n=102) or no intraepithelial lesion (non-IL; n=39). Cytological diagnosis was performed according to the Bethesda System (36), and histological diagnosis was performed according to the classification system of the International Federation of Gynecology and Obstetrics (37). Clinical data from the patients was obtained from the database of the Molecular Biomedicine and Cytology Laboratories at the School of Chemistry and Biology, Autonomous University of Guerrero.
Analysis of HPV 16 and 18 integrations using qPCR. The physical state of HPV 16 was analyzed using qPCR, amplifying two regions of the E2 gene and a region of the E6 gene using the following primers and TaqMan probes (Applied Biosystems; Thermo Fisher Scientific, Inc.): E2A region (transactivation domain) forward, 5'-TGATATACAGTGAGGAATGCAGTTG-3' and reverse, 5'-CCACAGTTCTCTGTCTTCCACATCA-3' primers, and 5'FAM-ATGAGACATATGCACACCTAA-3' NFQ probe; E2B region (hinge) forward, 5'-CAGGACAGCAATCTCCCTCTCTCCT-3' and reverse, 5'-GCGACGCAGTTGCTATGCGG-3' primers, and 5'FAM-ACGGTGTTGAATGTGTC-3' NFQ probe; and E6 region forward, 5'-ACGGTGTTGATGATTGGTAAC-3' and reverse, 5'-GCTTTTGTCCAGATGCTTTTCCTT-3' primers, and 5'FAM-AAA GCCACTGTGCTCTG-NFQ probe.

Similarly, the physical state of HPV 18 was analyzed by amplifying two regions of the E2 gene and a region of the E6 gene using the following primers and TaqMan probes (Applied Biosystems; Thermo Fisher Scientific, Inc.): E2N1 region (transactivation domain) forward, 5'-GACAACCTATTGTTTGGAATATCG-3' and reverse, 5'-GCTGGCACCACTTGGT-3' primers, and 5'FAM-CTGTAGTGCCATGTC-3' NFQ probe; E2H1 region forward, 5'-GATTGTAAATGCCTATGTCACCACTCCCT-3' and reverse, 5'-GCGTGCTCCACTTCTTGC-3' primers, and 5'FAM-AGCCCAGCTTATTAGGTGTAAC-3' NFQ probe; E6 region forward, 5'-ACGTTTGTGAATGTGTC-3' and reverse, 5'-GCTTTTGTCCAGATGCTTTTCCTT-3' primers, and 5'FAM-AAA GCCACTGTGCTCTG-NFQ probe.

To calculate the number of cells, a region of the RNase P single copy gene was amplified using forward, 5'-AGATTCTGGACCTGGGAG-3' and reverse, 5'-GAGCGGCCTGTCTCCAAAGAT-3' primers, and a VIC-TTCTGACCTGAAGGCCTTGCAGGAC-TAMRA RNase P probe (cat no. 4403328 Applied Biosystems; Thermo Fisher Scientific, Inc.).

In all cases, PCR was performed in a final volume of 10 µl containing 50 ng DNA, 5 µl Universal MasterMix II (Applied Biosystems; Thermo Fisher Scientific, Inc.) and 0.5 µl of a mix containing specific primers and probes for each gene and region. DNA amplification by qPCR was performed in an ABI-PRISM 7500 (Applied Biosystems; Thermo Fisher Scientific, Inc.) using the following thermocycler conditions: 50°C for 2 min, 95°C for 10 min, followed by 40 cycles of 95°C for 15 sec and 60°C for 1 min as previously described by Zhang et al (40). All reactions were run in duplicate, and the results were averaged for analysis. The positive control consisted of DNA from the SiHa cell line which contains 1-2 integrated copies of the HPV 16 genome as previously described by Flores et al (41) and Saunier et al (42), and the HeLa cell line, which contains integrated HPV 18. The negative controls consisted of the reaction components without DNA.

A standard curve for the quantification of the RNase P gene was generated using the commercial kit Taqman Copy Number Reference Assay RNase P (Applied Biosystems; Thermo Fisher Scientific) with genomic DNA obtained from 10,000, 5,000, 2,500, 1,250 and 625 cells. Standard curves for the E2 and E6 genes were generated by determining the quantification cycle (Cq) (43) value of detection with concentrations of 10^6, 10^5, 10^4, 10^3 and 10^2 copies/µl of plasmids containing the HPV 16 or HPV 18 genome as was performed by Zhang et al (40). All assays were performed in duplicate. The number of copies of each gene (x) in the sample was calculated with the formula x=exp[(Y-b)/m] where Y is the Cq value, and b and m are constant values obtained from the equation graph for the standard curve of each gene (44).

The physical state of HPV 16 was determined by calculating the ratios of E2A/E6 and E2B/E6. To ensure the validity of the method, these ratios were determined using the standard curves obtained from various dilutions of pUC8 and DNA from SiHa cells; pUC8 contains the complete HPV 16 genome, representing the episomal form, and SiHa cells were used as the integrated form (44). Viral genome integration was defined by the absence of E2 or an E2/E6 ratio of <0.0010. An E2A/E6 ratio of 0.0010-0.9270 was defined as a mixture of episomal and integrated forms. A ratio of >0.9270 was defined as the episomal form. An E2B/E6 ratio of 0.0010-0.9116 was defined as mixed form, and an E2B/E6 ratio of >0.9116 was defined as the episomal form (40).

The physical state of HPV 18 was determined by calculating the ratios of E2N1/E6 and E2H1/E6. To ensure the validity of this method, these ratios were determined using standard curves obtained from various dilutions of a plasmid containing the HPV 18 genome, representing the episomal form. Viral genome integration was defined by the absence of E2 or an E2/E6 ratio of <0.0010. An E2N1/E6 ratio of 0.0010-0.9151 was defined as the mixed form, and >0.9151 was defined as the episomal form. An E2H1/E6 ratio of 0.0010-0.9206 was defined as the mixed form, and an E2H1/E6 ratio >0.9206 was defined as the episomal form (40).

Analysis of HPV 16 and 18 integrations using ISH. Detection of HR-HPV genome integration was performed using ISH with a GenPoint Tyramide Signal Amplification system (Dako; Agilent Technologies, Inc., Santa Clara, CA, USA). Cytological samples were placed in a solution of acetone for 5 min at room temperature. The monolayer smears were digested for 1 min at 37°C with proteinase K (Invitrogen; Thermo Fisher Scientific, Inc.; 1:1,000). Biotinylated viral DNA with probes for 13 HR-HPV genotypes (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59 and 68) and individual
probes (Dako; Agilent Technologies, Inc.) directed at HPV 6 and HPV 11 were subsequently applied. The slides were denatured for 10 min at 95˚C, hybridized with a biotinylated HPV DNA probe (Dako; Agilent Technologies, Inc.) for 20 h at 37˚C and then placed in an astringent solution (1:50) at 55˚C for 20 min. Primary streptavidin peroxidase (1:100) was added for 40 min at room temperature, followed by biotinyl-tyramide for 20 min at 37˚C, and horse-radish peroxidase conjugated streptavidin (cat no. N100; Thermo Fisher Scientific, Inc.) undiluted, as the secondary antibody, was subsequently added for 20 min at 37˚C. The chromogen 3,3’-diaminobenzidene (Dako; Agilent Technologies, Inc.) was then added and Mayer’s hematoxylin (Merck KGaA, Darmstadt, Germany) at 37˚C for 10 sec was used as a contrast dye. Positive reactions were visualized as brown inside of the nucleus in a LEICA DM 1000 light microscope and, according to the type of signal, were classified as diffuse (epithelial state), punctate (intermediate state) or diffuse and punctate (mixed state) (30,31,33). SiHa cell lines (containing HPV 16) were used as positive controls to demonstrate an integrated state; the same cell lines without probes were used as negative controls.

Statistical analysis. L1MR was compared between groups using one-way analysis of variance and Tukey’s multiple comparison test as a post-hoc test using GraphPad Prism V5-03 software (GraphPad Software, Inc., La Jolla, CA, USA). P<0.05 was considered to indicate a statistically significant difference. Odds ratios (ORs) were calculated to determine the risk of lesion progression due to the methylation of specific CpG sites using STATA version 11 software (StataCorp LLC, College Station, TX, USA; http://www.stata.com/). Concordance between the various methods for the detection of viral integration was also calculated (45).

Results

Methylation of the HPV 16 and HPV 18 L1 gene in cervical specimens from women with CC, SIL and non-IL. The methylation status of the HPV 16 and HPV 18 L1 gene was evaluated in 187 cervical specimens from women with CC, HSIL, LSIL and non-IL. The median HPV 16 L1MRs were 20.2% for non-IL, 30.0% for LSIL, 33.0% for HSIL and 58.6% for CC. The HPV 16 L1MR was associated with histological grade, as statistically significant differences were identified in the following comparisons: LSIL vs. CC (P<0.0001) and non-IL vs. CC (P<0.0001; Fig. 1A). For HPV 18, the median L1MRs were 73.3% for non-IL, 64.1% for LSIL, 69.7% for HSIL and 85.7% for CC; however, these differences between histological grades were not significant (Fig. 1B).

A total of 12 CpG dinucleotides (from 5602 to 6580) in the HPV 16 L1 gene and 18 CpG sites (from 6015 to 7123) in the HPV 18 L1 gene were analyzed in specimens from patients with non-IL, LSIL, HSIL and CC. In HPV 16, the methylation of CpG sites 5608 and 5617 were associated with LSIL, the methylation of CpG sites 5602 and 5608 were associated with HSIL, and CpG sites 5608, 5617, 5709, 5726, 5926, 5962 were associated with CC. The strongest association with CC was CpG site 5617 (OR, 42.5; 95% confidence interval, 4.7-1861; P<0.0001), followed by CpG sites 5926, 5608, 5709 and 5962. Only CpG site 5608 was associated with all grades of cervical lesions. In CC samples, the highest L1MR was at CpG site 5617 (71.4%) (Fig. 2A).

High L1MRs at CpG sites in HPV 18 were detected in all grades of cervical lesions. 100% methylation was detected at 10 CpG sites in CC; 5 CpG sites in HSIL, 5 CpG sites in LSIL and 5 CpG sites in non-IL samples. However, the methylation differences in CC, HSIL, LSIL compared with non-IL were not significant (Fig. 2B).

Analysis of HPV 16 and HPV 18 integration using qPCR, ISH and L1 methylation. The physical statuses of HPV 16 and HPV 18 were evaluated using qPCR, ISH and L1 methylation in cervical specimens from CC, HSIL, LSIL and non-IL. HPV 18 was more frequently integrated compared with HPV 16; HPV 18 was integrated in 50% (qPCR), 100% (ISH) and 67% (L1 methylation) of CC specimens, whilst HPV 16 was integrated in 52% (qPCR), 92% (ISH) and 16% (L1 methylation) of CC specimens. Non-IL and LSIL demonstrated high rates of integration of HPV 16, as follows: 50 and 39% by qPCR, 33 and 45% by ISH, and only 6 and 7% by L1 methylation, respectively. HPV 18 was not integrated in non-IL, according to the qPCR and ISH analyses, but did exhibit integration in LSIL (10% by qPCR, 53% by ISH and 25% by L1 methylation; Table I).

The concordance rate between qPCR and ISH for the detection of the physical status of HPV 16 and HPV 18 was 96.1%. The concordance rates between qPCR and L1 methylation, and between ISH and L1 methylation were 76.7 and 84.8%, respectively (Table II).
Figure 2. Methylation in the L1 gene at various CpG sites in (A) HPV 16 and (B) HPV 18 in non-IL, LSIL, HSIL and CC. The x-axis indicates each individual CpG site by the nucleotide position in the L1 gene. HPV, human papillomavirus; non-IL, non-intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CC, cervical carcinoma; OR, odds ratio; CI, confidence interval.
**Table I. Physical status of HPV 16 and HPV 18 determined by qPCR, ISH and L1 methylation.**

| Diagnosis | qPCR (n=100) | ISH (n=140) | L1 methylation (n=154) |
|-----------|--------------|-------------|------------------------|
|           | Episomal (n=2) | Mixed (n=52) | Integrated (n=46) | Episomal (n=4) | Mixed (n=66) | Integrated (n=70) | Episomal (n=51) | Mixed (n=91) | Integrated (n=12) |
| Non-IL    | 1 (4)        | 12 (46)     | 13 (50)     | 3 (10)         | 17 (57)     | 10 (33)       | 17 (52)        | 16 (48)      | 0 (6)         |
| LSIL      | 1 (2)        | 27 (59)     | 18 (39)     | 1 (1)          | 43 (54)     | 36 (45)       | 28 (34)        | 48 (59)      | 6 (7)         |
| HSIL      | 0 (0)        | 1 (33)      | 2 (67)      | 0 (0)          | 4 (67)      | 2 (33)        | 4 (45)         | 4 (45)       | 1 (10)        |
| CC        | 0 (0)        | 12 (48)     | 13 (52)     | 0 (0)          | 2 (8)       | 22 (92)       | 2 (7)          | 23 (77)      | 5 (16)        |

**B, HPV 18 physical status, n (%)**

| Diagnosis | qPCR (n=19) | ISH (n=30) | L1 methylation (n=33) |
|-----------|--------------|-------------|------------------------|
|           | Episomal (n=5) | Mixed (n=12) | Integrated (n=2) | Episomal (n=1) | Mixed (n=14) | Integrated (n=15) | Episomal (n=0) | Mixed (n=23) | Integrated (n=10) |
| Non-IL    | 2 (67)        | 1 (33)      | 0 (0)      | 1 (17)         | 5 (83)      | 0 (0)         | 0 (0)          | 4 (67)       | 2 (33)        |
| LSIL      | 1 (10)        | 8 (80)      | 1 (10)     | 0 (0)          | 9 (47)      | 10 (53)       | 0 (0)          | 15 (75)      | 5 (25)        |
| HSIL      | 2 (50)        | 2 (50)      | 0 (0)      | 0 (0)          | 0 (0)       | 2 (100)       | 0 (0)          | 3 (75)       | 1 (25)        |
| CC        | 0 (0)         | 1 (50)      | 1 (50)     | 0 (0)          | 0 (0)       | 3 (100)       | 0 (0)          | 1 (33)       | 2 (67)        |

HPV, human papillomavirus; qPCR, quantitative polymerase chain reaction; ISH, *in situ* hybridization; non-IL, non-intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; CC, cervical carcinoma.

**Discussion**

The purpose of the present study was to investigate L1 gene methylation between various grades of cervical lesions positive for HPV 16 or HPV 18. Additionally, L1 methylation, ISH and qPCR were compared as methods with which to determine the integration of HPV 16 and HPV 18 in cervical specimens, including CC, premalignant lesions and non-cervical lesions.

The results indicated that the HPV 16 L1 gene undergoes a significant progressive increase in methylation rate according to the increase of the grade of the cervical lesion, in concordance with previous studies (23,28,46-48). However, higher methylation rates in non-IL and LSIL specimens were observed in the present study compared with those in a previous study (28).

Methylation of L1 increases progressively through the four pathological categories (non-IL, LSIL, HSIL and CC). However, methylation is also present in the absence of a cervical lesion in pathological categories (non-IL, LSIL, HSIL and CC). However, higher methylation rate in non-IL and LSIL specimens was observed in the present study compared with those in a previous study (28).

The increase of the grade of the cervical lesion, in concordance with previous studies (23,28,46-48). However, higher methylation rate in non-IL and LSIL specimens was observed in the present study compared with those in a previous study (28).

Methylation of L1 increases progressively through the four pathological categories (non-IL, LSIL, HSIL and CC). However, methylation is also present in the absence of a cervical lesion in pathological categories (non-IL, LSIL, HSIL and CC). However, higher methylation rate in non-IL and LSIL specimens was observed in the present study compared with those in a previous study (28).

**HPV 18 is lowest in cases of asymptomatic infection and increases progressively during the progression into cancer.**

Kalantari *et al* (47) hypothesized that highly methylated LSIL and HSIL samples are those that have undergone certain molecular changes that predispose them to develop into cancer. The present study concurs with this hypothesis, however, the level of methylation should be taken into account even in patients without cervical lesions, as this may indicate the possibility of lesion progression.

The usefulness of specific sites of methylation in the HPV genome in identifying women who are at an increased risk of developing CC has been suggested previously (24,48-50).

In the present study, 12 methylation CpG sites of the HPV 16 L1 gene were analyzed in samples from non-IL, LSIL, HSIL and CC tissues. Methylation of the 5608 CpG site was associated with the development of LSIL, HSIL and CC, whilst the methylation of the 5617 CpG site was associated with LSIL and CC, and the methylation of the 5709, 5726, 5926 and 5962 CpG sites was associated exclusively with CC. Mirabello *et al* (48) identified a strong association between methylation at the 6457 CpG site and CIN2 (HSIL), and in a subsequent study a strong association between methylation at the 5602, 5608, 5617 and 5617 CpG sites and cervical precancerous tissue was revealed (50). Sun *et al* (29) revealed increased methylation of the CpG sites in HPV 16 L1 associated with CIN1, CIN2 and CIN3 (LSIL/HSIL). Lorincz *et al* (24) reported a higher methylation of the 6367 and 6389 L1 CpG sites in women with CIN2/3. Branda *et al* (51) reported that the frequency of methylation was the highest for CIN3, followed by CIN2.
and CIN1 at the 5602, 5608, 5709, 5726, 6367, 6389, 6581 (referred to as 5600, 5606, 5707, 5724, 6365, 6387 and 6579) L1 CpG sites. The results of the present study coincide with the aforementioned studies, and the observed differences in what the sites of CpG methylation in the HPV 16 L1 gene have been identified to be may be due to the circulating HPV 16 variants in each geographical region. A previous study performed in the state of Guerrero in Southern Mexico revealed 27 variants of HPV 16 that belong to European and Asian-American sub-lineages (52). Nucleotide differences between variants may determine changes in HPV 16 methylation.

There is increasing evidence that the elevated methylation of specific HPV 16 CpG sites in the L1 gene ORF may be a biomarker of progression from premalignant lesions to CC. The present study concurs with Mirabello et al (48) in that a methylation assay in one or a small number of CpG sites would be easier to perform, minimize costs and could potentially serve as a prognostic biomarker to predict the development of premalignant lesions and CC.

In HPV 18, analysis of 18 CpG sites was performed in all grades of cervical lesions, revealing that none of the sites were significantly associated with the development of CC or premalignant lesions. However, high L1MRs in a number of CpG sites were detected in non-IL, LSIL, HSIL and CC, which may indicate that potentially certain changes have occurred that predispose the tissue to develop into cancer, as proposed by Kalantari et al (47), considering that viral methylation appears to occur years prior to the detection of premalignant lesions (48).

The integration of HR-HPV genomes is a key event in cervical carcinogenesis, as it contributes to neoplastic transformation. The integration of viral genomes is a consequence of chromosomal instability induced by deregulated E6 and E7 oncogene expression (53). There are several methods that may be used in order to detect HPV integration in the human genome, including qPCR (20), ISH (30,31) and L1 methylation (18). However, few studies have compared such methods by which to determine the physical state of HPV. Fujii et al (54) compared ISH with qPCR using SIL and CC samples, reporting an 86% concordance rate between the two methods. Biesaga et al (55) additionally compared ISH with qPCR to assess the physical viral genome state in CC samples.
and revealed no significant difference between these methods, concluding that ISH may be used for the assessment of viral genome status.

To the best of our knowledge, no previous studies comparing the use of qPCR, ISH and L1 gene methylation assay methods have been performed in order to evaluate HPV 16 integration. In the present study, these three methods were compared. Good concordance was identified between them, and each method possessed certain advantages. qPCR is a useful technique for detecting integrated and episomal forms of HPV. This method has the advantage of additionally calculating the viral copy numbers for episomal and integrated HPV, making it a prognostic tool for determining the risk of CC (20). L1 methylation is a frequent result of integration. Therefore, it has been proposed that L1 gene methylation indicates integration, and may be used as a potential biomarker of cancer progression (18,56). ISH with signal amplification by biotinyl tyramide to demonstrate HPV DNA has the advantage of preserving the histological context of a lesion and allows the detection of low-copy DNA (57). It is generally accepted that a diffuse signal indicates an episomal status and that punctate signals indicate integrated HPV (31). The ISH assay with signal amplification by biotinyl tyramide is convenient for clinical purposes (58). According to the results of the present study, it has a high concordance rate with qPCR (96.1%) and also with the HPV L1 gene methylation assay (84.8%).

In conclusion, methylation of the HPV 16 L1 gene increases significantly according to the grade of cervical lesion. CpG site 5608 is associated with premalignant lesions and CC, whereas CpG site 5617 had the strongest association with CC; there CpG site 5608 is associated with premalignant lesions and CC, whereas CpG site 5617 had the strongest association with CC; there is no significant difference between these methods, concluding that ISH may be used for the assessment of viral genome status.

Acknowledgements

The present study was supported by the National Council of Science and Technology (grant no. 201579). The authors would like to thank Dr Marco Antonio Jiménez-López of the Cancer Institute of the State of Guerrero ‘Dr. Arturo Beltrán Ortega’ for the histopathological diagnosis, and the technicians of the Cytopathology and Histochemistry Laboratory (School of Chemical and Biological Sciences, Autonomous University of Guerrero) for their assistance.

References

1. zur Hausen H: Papillomaviruses and cancer: From basic studies to clinical application. Nat Rev Cancer 2: 342-350, 2002.
2. Muñoz N, Bosch FX, de Sanjose S, Herrero R, Castellsagué X, Shah KV, Snijders PJ and Meijer CJ: International Agency for Research on Cancer Multicenter Cervical Cancer Study Group: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 348: 518-527, 2003.
3. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC Cancer Base No. 11 Internet. Lyon, France: International Agency for Research on Cancer, 2013. Available from: http://globocan.iarc.fr, accessed on 17/09/2017.
4. Bruni LB-R L, Serrano B, Brotons M, Cosano R, Munoz J, Bosch FX, de Sanjose S and Castellsagué X: ICO Information centre on HPV and cancer (HPV Information Centre). Human Papillomavirus and Related Diseases in Mexico. Summary Reports, 2014.
5. Secretaría de Salud. Información estadística. Estadísticas de cáncer cervicouterino, https://www.gob.mx/cms/uploads/attachment/file/12951/MortalidadCaCu2000a2013.pdf accessed on 17/05/2016.
6. Ilades-Aguir Alarcon-Romero Ldel C, Antonio-Véjar V, Zamudio-López N, Sales-Linares N, Flores-Alfaro E, Fernández-Tilapa G, Vences-Velázquez A, Muñoz-Valle JF and Leyva-Vázquez MA: Prevalence and distribution of human papillomavirus types in cervical cancer, squamous intraepithelial lesions, and with high-risk epithelial lesions in women from Southern Mexico. Gynecol Oncol 117: 291-296, 2010.
7. Pinto AP, Degen M, Villa LL and Cibas ES: Immunomarkers in gynecologic cytology: The search for the ideal ‘biomolecular Papanicolaou test’. Acta Cytol 56: 109-121, 2012.
8. Pett M and Coleman N: Integration of high-risk human papillomavirus: A key event in cervical carcinogenesis? J Pathol 212: 356-367, 2007.
9. Badaracco G, Venuti A, Sedati A and Marcante ML: HPV16 and HPV18 in genital tumors: Significantly different levels of viral integration and correlation to tumor invasiveness. J Med Virol 67: 574-582, 2002.
10. Kalantari M, Karlsen F, Kristensen G, Holm R, Hagmar B and Johansson B: Disruption of the E1 and E2 reading frames of HPV 16 in cervical carcinoma is associated with poor prognosis. Int J Gynecol Pathol 17: 146-153, 1998.
11. Romanowczuk H and Holm R: Disruption of either the E1 or the E2 regulatory gene of human papillomavirus type 16 increases viral immortalization capacity. Proc Natl Acad Sci USA 89: 3159-3163, 1992.
12. Jeon S and Lambert PF: Integration of human papillomavirus type 16 DNA into the human genome leads to increased stability of E6 and E7 mRNAs: Implications for cervical carcinogenesis. Proc Natl Acad Sci USA 92: 1654-1658, 1995.
13. Kalantari M, Blennow E, Hagmar B and Johansson B: Physical state of HPV16 and chromosomal mapping of the integrated form in cervical carcinomas. Diagn Mol Pathol 10: 46-54, 2001.
14. Kalantari M, Villa LL, Calleja-Macias IE and Bernard HU: Human papillomavirus-16 and -18 in penile carcinomas: DNA methylation, chromosomal recombination and genomic variation. Int J Cancer 123: 1832-1840, 2008.
15. zur Hausen H: Papillomaviruses causing cancer: Evasion from host-cell control in early events in carcinogenesis. J Natl Cancer Inst 92: 690-698, 2000.
16. Gallo G, Bibbo M, Bagella L, Zamparelli A, Sanseverino F, Giovagnoli MR, Vecchione A and Giordano A: Study of viral integration of HPV-16 in young patients with LSI1. J Clin Pathol 56: 532-536, 2003.
17. Huang LW, Chao SL and Lee BH: Integration of human papillomavirus type-16 and type-18 is a very early event in cervical carcinogenesis. J Clin Pathol 61: 627-631, 2008.
18. Kalantari M, Chase DM, Tewari KS and Bernard HU: Recombination of human papillomavirus-16 and host DNA in exfoliated cervical cells: A pilot study of L1 gene methylation and chromosomal integration as biomarkers of carcinogenic progression. J Med Virol 82: 3159-3163, 2010.
19. Kulmala SM, Syrjänen SM, Gyllensten UB, Shabalova IP, Petrovichiev N, Toi P, Syrjänen KJ and Johansson BC: Early integration of high copy HPV16 detectable in women with normal and low grade cervical cytology and histology. J Clin Pathol 59: 513-517, 2006.
20. Peitsaro P, Johannson B and Syrjänen S: Integrated human papillomavirus type 16 is frequently found in cervical cancer precursors as demonstrated by a novel quantitative real-time PCR technique. J Clin Microbiol 40: 886-891, 2002.
21. Das P, Thomas A, Mahantshetty U, Shrivastava SK, Deodhar K and Mulherkar R: HPV genotyping and site of viral integration in cervical cancers in Indian women. PLoS One 7: e41012, 2012.
22. Bird A: DNA methylation patterns and epigenetic memory. Genes Dev 16: 6-21, 2002.
23. Kalantari M, Calleja-Macias IE, Tewari D, Hagmar B, Lie K, Barrera-Saldana HA, Wiley DJ and Bernard HU: Conserved methylation patterns of human papillomavirus type 16 DNA in asymptomatic infection and cervical neoplasia. J Virol 87: 12762-12772, 2004.
24. Lorincz AT, Brentnall AR, Vasiljevic N, Scibior-Bentkowska D, Castanon A, Fiander A, Powell N, Tristram A, Cuzick J and Sasienski P: HPV16 L1 and L2 DNA methylation predicts high-grade cervical intraepithelial neoplasia in women with mildly abnormal cervical cytology. Int J Cancer 133: 637-644, 2013.

25. Turan T, Kalantari M, Calleja-Macias IE, Cubie HA, Cuschieri K, Villal Abstracts L, Skomedal H, Barrera-Saldana HA and Bernard HU: Methylation of the human papillomavirus-18 L1 gene: A biomarker of neoplastic progression? Virology 349: 175-183, 2006.

26. Turan T, Kalantari M, Cuschieri K, Cubie HA, Skomedal H and Bernard HU: High-throughput detection of human papillomavirus-18 L1 gene methylation, a candidate biomarker for the progression of cervical neoplasia. Virology 361: 185-193, 2007.

27. Brandsma JL, Sun Y, Lizardi PM, Tuck DP, Zeltzerman D, Haines GK III, Martel M, Harigopal M, Schofield K and Neapolitano M: Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology 389: 100-107, 2009.

28. Oka N, Kajita M, Nishimura R, Ohbayashi C and Sudo T: L1 gene methylation in high-risk human papillomaviruses for the prognosis of cervical intraepithelial neoplasia. Int J Gynecol Cancer 23: 235-243, 2013.

29. Sun C, Reimers LL and Burk RD: Methylation of HPV16 genome CpG sites is associated with cervix precancer and cancer. Gynecol Oncol 121: 59-63, 2011.

30. Evans MF, Aliesky HA and Cooper K: Optimization of biotinyl-tyrimate-based in situ hybridization for sensitive background-free applications on formalin-fixed, paraffin-embedded tissue. Diagn Mol Pathol 10: 518-521, 2001.

31. Evans MF, Mount SL, Beatty BG and Cooper K: Biotinyl-tyrimate-based in situ hybridization signal patterns distinguish human papillomavirus type and grade of cervical intraepithelial neoplasia. Mod Pathol 15: 1339-1347, 2002.

32. Zubiagila-Guerrero MI, Illades-Aguilar B, Flores-Alfaro E, Lopez-Bayghen E, Leiva-Vazquez MA, Castaneda-Saucedo E and Alarcón-Romo Ldel C: Risk of progression of early cervical lesions is associated with integration and persistence of HPV16 and expression of E6, KI-67, and telomerase. J Cytol 30: 226-232, 2013.

33. Zubiagila-Guerrero MI, Illades-Aguilar B, Flores-Alfaro E, Leiva-Vazquez MA, Castaneda-Saucedo E, Muñoz-Valle JF and Alarcón-Romo Ldel C: The integration of HR-HPV increases the expression of cyclins A and E in cytologies with and without low-grade lesions. J Cytol 30: 1-7, 2013.

34. Ausubel F, Brent R, Kingston R, Moore D, Seidman JG, Smith JA, Struhl K: Short Protocols in Molecular Biology, pp2-3, 1995.

35. Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, Solomon D, Davey D, Kurman R, Moriarty A, O’Connor D, Prey M, Raab S, Sherman M, Wilbur D, Wright T Jr, et al: The 2001 Bethesda system: Terminology for reporting results of HPV testing and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517, 1999.

36. Bryan JT, Taddeo F, Skulsky D, Jansen KU, Frain BM, Qadadri B, Bryan JT, Taddeo F, Skulsky D, Jansen KU, Frain BM, Qadadri B, et al: Comparison of the sensitivity and specificity of real-time PCR and in situ hybridization in HPV16 detection in cervical cancer specimens. Folia Histochem Cytobiol 50: 239-247, 2012.

37. Anderson K, Bao M, Chakraborty K, Gallo R, Gotoff P, Quint W: Development and clinical evaluation of a highly sensitive, rapid human papillomavirus test: Evaluation in cervical screening and in the management of gynecologic cancers. FIGO Committee on FIGO staging classifications and clinical practice guidelines in cervical cancer. FIGO 2001 Bethesda system: Terminology for reporting results of HPV testing and identification of anogenital human papillomavirus. J Clin Microbiol 37: 2508-2517, 1999.

38. Bryan JT, Taddeo F, Skulsky D, Jansen KU, Frain BM, Qadadri B, Bryan JT, Taddeo F, Skulsky D, Jansen KU, Frain BM, Qadadri B, et al: Comparison of the sensitivity and specificity of real-time PCR and in situ hybridization in HPV16 detection in cervical cancer specimens. Folia Histochem Cytobiol 50: 239-247, 2012.

39. Bryant D, Tristram A, Liloglou T, Hibbitts S, Fiander A and Bryant D, Tristram A, Liloglou T, Hibbitts S, Fiander A, et al: Evaluation of twelve CpGs in human papillomavirus type 16 (HPV16) as an informative biomarker for the triage of women positive for HPV16 infection. Cancer Prev Res (Phila) 7: 526-533, 2014.

40. Ortiz-Ortiz J, Alarcón-Romo Ldel C, Jiménez-Lopez MA, Ortiz-Ortiz J, Alarcón-Romo Ldel C, Jiménez-Lopez MA, et al: Analysis of human papillomavirus type 16 E6 variants with cervical carcinoma and precursor lesions in women from Southern Mexico. Virol J 12: 29, 2015.

41. Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, Vinokurova S, Wentzensen N, Kraus I, Klaes R, Driesch C, et al: Distinct human papillomavirus type 16 and 18 L1 gene methylation, a candidate biomarker for the prediction of cervical cancer risk among Chinese women. J Med Virol 85: 646-654, 2013.

42. Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briot L, Saunier M, Monnier-Benoit S, Mauny F, Dalstein V, Briot L, et al: High-risk human papillomavirus (HR-HPV) DNA load and physical status as identifiers of HPV16-infected women with high-grade lesions or cervical carcinoma. J Clin Microbiol 46: 3678-3685, 2008.

43. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(ΔΔC(T)) method. Methods 25: 402-408, 2001.

44. Zhang D, He X, Yu G and Wu Y: Efficiency of HPV 16 viral load and the E2/E6 ratio for the prediction of cervical cancer risk among Chinese women. J Med Virol 85: 646-654, 2013.

45. Kwiecien R, Kopp-Schneider A and Blettner M: Concordance analysis: Part 16 of a series on evaluation of scientific publications. Disch Arztebl 108: 1015-1021, 2011.

46. Fernandez AF, Rosales C, Lopez-Nieva P, Gradell L, Ropero S, Espada J, Melo SA, Lujambio A, Fraga MF, et al: The dynamic DNA methylomes of double-stranded DNA viruses associated with human cancer. Genome Res 19: 438-451, 2009.

47. Kalantari M, Osatkin K, Calleja-Macias IE, Kim S, Yan B, Jordan S, Chase DM, Tewari KS and Bernard HU: Methylation of human papillomavirus 16, 18, 31, and 45 L1 and L2 genes and the cellular DAPK gene: Considerations for use as biomarkers of the progression of cervical neoplasia. Virology 448: 314-321, 2014.